Igene Biotechnology, Inc.
IGNE · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Revenue | $3,958 | $7,644 | $2,287 | $0 |
| % Growth | -48.2% | 234.3% | – | – |
| Cost of Goods Sold | $2,942 | $6,395 | $1,682 | $0 |
| Gross Profit | $1,016 | $1,249 | $605 | $0 |
| % Margin | 25.7% | 16.3% | 26.5% | – |
| R&D Expenses | $1,851 | $1,656 | $984 | $848 |
| G&A Expenses | $838 | $1,051 | $973 | $1,022 |
| SG&A Expenses | $1,226 | $1,782 | $1,131 | $1,120 |
| Sales & Mktg Exp. | $388 | $731 | $158 | $98 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $991 | $3,438 | $538 | $307 |
| Operating Income | -$1,070 | -$2,188 | $238 | -$417 |
| % Margin | -27% | -28.6% | 10.4% | – |
| Other Income/Exp. Net | $1,070 | $226 | $24 | $15 |
| Pre-Tax Income | -$43 | -$1,962 | $262 | -$402 |
| Tax Expense | $165 | $1,803 | $1,966 | $848 |
| Net Income | -$141 | -$3,991 | -$1,899 | -$1,156 |
| % Margin | -3.6% | -52.2% | -83% | – |
| EPS | -0 | -0.021 | -0.017 | -0.011 |
| % Growth | 99.5% | -23.1% | -61.7% | – |
| EPS Diluted | -0 | -0.021 | -0.017 | -0.011 |
| Weighted Avg Shares Out | 1,537,790 | 187,037 | 109,680 | 108,387 |
| Weighted Avg Shares Out Dil | 1,537,790 | 187,037 | 109,680 | 108,387 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $98 | $2,028 | $2,161 | $754 |
| Depreciation & Amortization | $151 | $108 | $12 | $16 |
| EBITDA | -$851 | -$2,080 | $325 | -$308 |
| % Margin | -21.5% | -27.2% | 14.2% | – |